Radiopharmaceuticals — US PTAB Patent Cases
3 decisions indexed
Page 1 of 1 · 3 total
GE Healthcare Ltd. et al. v.The Johns Hopkins University et al.
GE Healthcare petitions to invalidate Johns Hopkins’s 11,938,201 patent covering FAP‑targeting radiopharmaceuticals, arguing that claims 1‑3 are obvious over US‑633, US‑121, Meletta and Jansen references.
AdvanCell Pty Ltd. v.Sciencons AS et al.
AdvanCell has filed a PGR petition seeking cancellation of all 38 claims of U.S. Patent 12,249,437, arguing anticipation, obviousness, and indefiniteness based on prior art from Hassfjell‑Hoff, Norman, IAEA, and Westrøm.
Curium US LLC v.Universität Heidelberg et al.
Curium US LLC petitions the PTAB to institute an IPR against the ‘901 patent covering alpha‑emitter PSMA‑targeted therapies, arguing obviousness and anticipation over multiple prior‑art references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.